Interleukin 6 IL 6 Receptor IL 6R - Biotech, Pharma and Life Science Channel
Although the causes of rheumatoid arthritis are not fully understood, constitutive overproduction of interleukin-6 (IL-6), a multifunctional cytokine that regulates immune response, inflammatory reaction and bone metabolism, is thought to play a major pathological role in RA. With the recent approval of tocilizumab, a humanized anti-IL-6 receptor antibody originating from Chugai and under development at Roche in Western countries, this target has become clinically validated and now can show its commercial potential in competition with TNF blockers.
News Articles
ImmunoCellular Therapeutics Announces Issuance of Key Patent Covering ICT-107 Cancer Vaccine Target
ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT: IMUC) announced that the US Patent and Trademark Office (USPTO) has issued a patent covering methods of use of...
Idera Pharmaceuticals Reports First Quarter 2013 Financial Results
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today reported financial results for the quarter ended March 31, 2013. “Our next objective in Idera’s autoimmune dis...
Tokai Pharmaceuticals Announces $35.5 Million Series E Financing
Financing Reflects Encouraging Clinical Progress with Galeterone in Prostate Cancer Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developin...
Interleukin Genetics Reports First Quarter 2013 Financial Results
Interleukin Genetics, Inc. (OTCQB: ILIU) today issued financial and operational results for the first quarter ended March 31, 2013. Revenue for the quarter ended March ...
The U.S. Food and Drug Administration today approved the cobas EGFR Mutation Test, a companion diagnostic for the cancer drug Tarceva (erlotinib). This is the first FDA-approved companion diagnostic t...
Evidence Grows For The Use of Critical Diagnostics’ Biomarker, ST2, In Primary Disease Prevention Critical Diagnostics announced today that the Journal of Hypertension...
Neumedicines Inc., a privately held company developing therapies based on interleukin-12 (IL-12) as a radiation medical countermeasure and for the treatment of chemotherapy-induce...
CEL-SCI Corporation Reports Second Quarter 2013 Financial Results
CEL-SCI Corporation (NYSE MKT: CVM) reports financial results for the fiscal quarter ended March 31, 2013. CEL-SCI reported that net loss available to common shareholders...
PETACH TIKVA, Israel, May 10, 2013 /PRNewswire/ -- OphthaliX, Inc. (OTC BB: OPLI), announced today that it has come to its knowledge that Professor M. Francesca Cordeiro, a Professor of Glaucoma...
SAN DIEGO, May 9, 2013 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announces that PROCLIVITY 01, a multi-center study of Pro...
Events
None
Companies
Tokai Pharmaceuticals is a U.S. biopharmaceutical company focused on developing new treatments for prostate cancer. The companyâs lead drug candidate, TOK-001, is the first i...
Izun Pharmaceuticals Corporation
Izun Pharmaceuticals is a US based pharmaceutical company with a wholly owned R&D center in Israel. Izunâs technology platform allows it to develop botanical drugs by optimiz...
Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets a line of genetic tests under the Inherent Health® brand. The products empower individuals to prevent ce...
Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of majo...
Tokai Pharmaceuticals is a U.S. biopharmaceutical company focused on developing new treatments for prostate cancer. The companyâs lead drug candidate, galeterone (TOK-001), i...
EnVivo Pharmaceuticals, Inc. and its subsidiaries (âEnVivo Pharmaceuticalsâ or âEnVivoâ) are dedicated to discovering and developing small molecule therapeutic...
bioTheranostics discovers, develops, and commercializes a growing array of molecular diagnostic tests for cancer patients. Leveraging its unique expertise in expression profiling...
Neumedicines Inc. is developing protein therapeutics that address unmet clinical and societal needs in the fields of oncology, hematology and immunology. The companyâs lead p...
Opsona is a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of majo...
Trevena, Inc. is a leader in the discovery and development of GPCR biased ligand drugs. Trevena combines a powerful and efficient drug discovery platform with extensive developmen...
Clinical Trials
Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy
Background: - Drugs given to treat cancer (chemotherapy) can weaken the human immune system. But it can also become weaker because of aging. Interleukin (IL)-7, a molecule produced natura...
RATIONALE: Aromatase inhibitors, such as letrozole, prevent the formation of estradiol, a female hormone. Giving letrozole together with goserelin, leuprolide, or surgery may be an effecti...
Usefulness of Myocardial Deformation Imaging for Trastuzumab-induced Cardiotoxicity
Trastuzumab prolongs survival in patients with human epidermal growth factor receptor type 2-positive breast cancer. Sequential left ventricular (LV) ejection fraction (EF) assessment has...
D-Serine Monotherapy for Schizophrenia
N-methyl-D-aspartate receptor (NMDAR) agonist, added to classical or atypical antipsychotic medication, has reduced negative, depressive, and cognitive symptomatology. We will be investiga...
D-Serine Adjuvant Treatment for Parkinson's Disease
The proposed experiment will evaluate the effects of the NMDA receptor full agonist D-serine (~2g/day) on persistent symptoms of Parkinson's Disease and on antiparkinsonian drugs-induced d...
The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria
An open labelled trial of Kineret (anakinra) induction therapy (100mg./day) in over a four week period in the treatment of Familial Cold Urticaria. Familial Cold Urticaria (FCU) is a rare...
Adenoscan® (adenosine) is an approved pharmacological stress agent indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. Th...
This feasibility study is designed to examine modulation of the relative activities of ACE and ACE2 in diabetic patients following treatment with the angiotensin type 1 receptor (AT1R) ant...
Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck
To determine safety profile of the epidermal growth factor receptor (EGFR) antagonist, ZD1839 in combination with cisplatin and radiation therapy in patients with local-regional recurrent...
The Effect of Caffeine on Ischemic Preconditioning
Ischaemic preconditioning (IP) describes the phenomenon that brief periods of ischaemia render the (myocardial) muscle more resistant to a subsequent more prolonged period of ischaemia and...
PubMed Articles
Estrogens and IL-12 play a pivotal role in the development and progression of non-small-cell lung cancer (NSCLC); at the same time, estrogen receptor β2 and (interleukin-12 receptor β2)IL-12Rβ2 are...
p73 gene shares structural and functional similarities to p53 and plays an important role in modulating cell cycle arrest and apoptosis. A common non-coding polymorphism of p73 G4C14-to-A4T14 (rs22739...
IL-32 expression is an independent prognostic marker for gastric cancer.
A strong link between inflammation and gastrointestinal cancer has been demonstrated. Interleukin (IL)-32 is a recently described pro-inflammatory cytokine characterized by the induction of nuclear fa...
P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer.
Expression of P2Y12 receptors has been documented in some cancer cell lines like C6 glioma, renal carcinoma and colon carcinoma. However, its direct role in altering response to chemotherapeutics has...
Prostate cancer (PCa) is one of the most commonly diagnosed malignancies in men and the second leading cause of male cancer mortality. MAZ (Myc-associated zinc-finger protein) is a transcription facto...
AIMS/HYPOTHESIS: The nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) is an important gene regulator in glucose and lipid metabolism. Unfortunately, PPARγ-activating drugs o...
Apoptosis can occur throughout the life span of osteoblasts (OBs), beginning from the early stages of differentiation and continuing throughout all stages of their working life. Here, we investigated...
Bcl10 is an essential regulator for A20 gene expression.
A20, a tumor suppressor in several types of lymphomas, has been suggested to be an nuclear factor kappa B (NF-κB) target gene; conversely, the deubiquitylation activity of A20 is required for inhibit...
BACKGROUND: To analyze the effects of supplemental epidermal growth factor (EGF) and the roles of inflammatory cytokines (interleukin [IL]-6) in an ex vivo dry-eye model under hyperosmotic stress usin...
The role of individual monocyte subsets in inflammation and recovery post-myocardial infarction (MI) is insufficiently understood. It was the objective of this study to evaluate the dynamics of monocy...
Videos
Tocilizumab action - video clip
Tocilizumab (Actemra and RoActemra) is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R) used as an immunosuppressive drug, mainly f...
Medical and Biotech [MESH] Definitions
Transferrin-binding Protein A
A subtype of bacterial transferrin-binding protein found in bacteria. It forms a cell surface receptor complex with TRANSFERRIN-BINDING PROTEIN B.
Transferrin-binding Protein B
A subtype of bacterial transferrin-binding protein found in bacteria. It forms a cell surface receptor complex with TRANSFERRIN-BINDING PROTEIN A.
Bacterial Transferrin Receptor Complex
A complex of proteins that forms a receptor for TRANSFERRIN in BACTERIA. Many pathogenic bacteria utilize the transferrin-binding complex to acquire their supply of iron from serum.
Receptors, Eph Family
A large family of receptor protein-tyrosine kinases that are structurally-related. The name of this family of proteins derives from original protein Eph (now called the EPHA1 RECEPTOR), which was named after the cell line it was first discovered in: Erythropoietin-Producing human Hepatocellular carcinoma cell line. Members of this family have been implicated in regulation of cell-cell interactions involved in nervous system patterning and development.
Receptor, Epha1
The founding member of the EPH FAMILY RECEPTORS. It was first cloned from an erythropoietin-producing human hepatocellular carcinoma cell line and is highly conserved among many mammalian species. Overproduction of the EphA1 receptor is associated with tumors and tumor cells of epithelial origin. It is also expressed at high levels in LIVER; LUNG; and KIDNEY; which is in contrast to many other members of the Eph receptor that are found primarily in tissues of the nervous system.
